114 related articles for article (PubMed ID: 26926669)
1. Management of Everolimus and Voriconazole Interaction in Lung Transplant Patients.
Outeda Macías M; Salvador Garrido P; Elberdín Pazos L; Martín Herranz MI
Ther Drug Monit; 2016 Jun; 38(3):305-12. PubMed ID: 26926669
[TBL] [Abstract][Full Text] [Related]
2. Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.
Lecefel C; Eloy P; Chauvin B; Wyplosz B; Amilien V; Massias L; Taburet AM; Francois H; Furlan V
J Clin Pharm Ther; 2015 Feb; 40(1):119-20. PubMed ID: 25417855
[TBL] [Abstract][Full Text] [Related]
3. Effect of fluconazole on the pharmacokinetics of everolimus and tacrolimus in a heart transplant recipient: Case report.
Nakagita K; Wada K; Terada Y; Matsuda S; Terakawa N; Oita A; Takada M
Int J Clin Pharmacol Ther; 2018 Jun; 56(6):270-276. PubMed ID: 29648533
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
Pea F; Baccarani U; Tavio M; Cojutti P; Adani GL; Londero A; Baraldo M; Franceschi L; Furlanut M; Viale P
Ann Pharmacother; 2008 Nov; 42(11):1711-6. PubMed ID: 18812562
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
6. Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient.
Billaud EM; Antoine C; Berge M; Abboud I; Lefeuvre S; Benammar M; Glotz D
Clin Drug Investig; 2009; 29(7):481-486. PubMed ID: 19499965
[TBL] [Abstract][Full Text] [Related]
7. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
Atiq F; Hameli E; Broers AEC; Doorduijn JK; Van Gelder T; Andrews LM; Koch BCP; Versmissen J; de Winter BCM
Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
Felipe CR; Oliveira NI; Hannun PG; de Paula MI; Tedesco-Silva H; Medina-Pestana JO
Ther Drug Monit; 2016 Feb; 38(1):64-72. PubMed ID: 26274696
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole Tablets in Real-Life Lung Transplantation: Impact on Exposure, Drug-Drug Interactions, and Drug Management in Lung Transplant Patients, Including Those with Cystic Fibrosis.
Launay M; Roux A; Beaumont L; Douvry B; Lecuyer L; Douez E; Picard C; Grenet D; Jullien V; Boussaud V; Guillemain R; Billaud EM
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311077
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus dosage requirements in lung transplant recipients receiving antifungal prophylaxis with voriconazole followed by itraconazole: a preliminary prospective study.
Enderby CY; Heckman MG; Thomas CS; Keller CA
Clin Transplant; 2014 Aug; 28(8):911-5. PubMed ID: 24931421
[TBL] [Abstract][Full Text] [Related]
11. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient.
Capone D; Tarantino G; Gentile A; Sabbatini M; Polichetti G; Santangelo M; Nappi R; Ciotola A; D'Alessandro V; Renda A; Basile V; Federico S
J Clin Pharm Ther; 2010 Feb; 35(1):121-4. PubMed ID: 20175821
[TBL] [Abstract][Full Text] [Related]
12. Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation.
van Gelder T; Fischer L; Shihab F; Shipkova M
Transplant Rev (Orlando); 2017 Jul; 31(3):151-157. PubMed ID: 28279567
[TBL] [Abstract][Full Text] [Related]
13. Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study.
Veenhof H; Schouw HM; Besouw MTP; Touw DJ; Gracchi V
Eur J Clin Pharmacol; 2020 Dec; 76(12):1667-1673. PubMed ID: 32712713
[TBL] [Abstract][Full Text] [Related]
14. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
Kovarik JM; Snell GI; Valentine V; Aris R; Chan CK; Schmidli H; Pirron U
J Heart Lung Transplant; 2006 Apr; 25(4):440-6. PubMed ID: 16563975
[TBL] [Abstract][Full Text] [Related]
15. Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients.
Vanhove T; Spriet I; Annaert P; Maertens J; Van Cleemput J; Vos R; Kuypers D
Ther Drug Monit; 2017 Feb; 39(1):77-82. PubMed ID: 27861314
[TBL] [Abstract][Full Text] [Related]
16. Analytical performance of QMS everolimus assay on ortho Vitros 5,1 FS fusion analyzer: measuring everolimus trough levels for solid organ transplant recipients.
Shu I; Wright AM; Chandler WL; Bernard DW; Wang P
Ther Drug Monit; 2014 Apr; 36(2):264-8. PubMed ID: 24232125
[TBL] [Abstract][Full Text] [Related]
17. Circadian pharmacokinetics and limited sampling strategy of everolimus in heart transplant patients
.
Terada Y; Wada K; Matsuda S; Kuwahara T; Kawabata A; Takada M; Watanabe T; Nakajima S; Sato T; Seguchi O; Yanase M; Fukushima N; Nakatani T
Int J Clin Pharmacol Ther; 2017 Jan; 55(1):1-8. PubMed ID: 27781420
[TBL] [Abstract][Full Text] [Related]
18. Management of voriconazole hepatotoxicity in a lung transplant patient.
Belaiche S; Roustit M; Bedouch P; Quetant S; Saint-Raymond C; Pison C
Transpl Infect Dis; 2011 Jun; 13(3):309-11. PubMed ID: 21176020
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation.
Lesche D; Sigurdardottir V; Setoud R; Englberger L; Fiedler GM; Largiadèr CR; Mohacsi P; Sistonen J
Clin Transplant; 2015 Dec; 29(12):1213-20. PubMed ID: 26458301
[TBL] [Abstract][Full Text] [Related]
20. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
